Geode Capital Management
MRNS

Geode Capital Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Geode Capital Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-529,053
Closed -$283K – 4575
2024
Q4 		$283K Sell
529,053
-39,464
-7% -$27.5K ﹤0.01% 3786
2024
Q3 		$1M Sell
568,517
-48,878
-8% -$68.2K ﹤0.01% 3354
2024
Q2 		$723K Sell
617,395
-597,371
-49% -$1.49M ﹤0.01% 3428
2024
Q1 		$11M Buy
1,214,766
+75,272
+7% +$732K ﹤0.01% 2268
2023
Q4 		$12.4M Buy
1,139,494
+94,546
+9% +$709K ﹤0.01% 2214
2023
Q3 		$8.41M Buy
1,044,948
+97,886
+10% +$814K ﹤0.01% 2371
2023
Q2 		$10.3M Buy
947,062
+499,839
+112% +$4.28M ﹤0.01% 2273
2023
Q1 		$3.09M Buy
447,223
+29,494
+7% +$185K ﹤0.01% 2843
2022
Q4 		$1.66M Buy
417,729
+82,573
+25% +$406K ﹤0.01% 3128
2022
Q3 		$2.23M Buy
335,156
+4,840
+1% +$29.8K ﹤0.01% 3047
2022
Q2 		$1.6M Sell
330,316
-308,900
-48% -$1.88M ﹤0.01% 3198
2022
Q1 		$5.98M Buy
639,216
+46,119
+8% +$458K ﹤0.01% 2696
2021
Q4 		$7.04M Buy
593,097
+15,281
+3% +$176K ﹤0.01% 2685
2021
Q3 		$6.58M Sell
577,816
-6,367
-1% -$87.6K ﹤0.01% 2754
2021
Q2 		$10.5M Buy
584,183
+79,608
+16% +$1.28M ﹤0.01% 2418
2021
Q1 		$7.81M Buy
504,575
+120,889
+32% +$1.75M ﹤0.01% 2524
2020
Q4 		$4.68M Buy
383,686
+36,888
+11% +$514K ﹤0.01% 2639
2020
Q3 		$4.46M Buy
346,798
+57,755
+20% +$498K ﹤0.01% 2457
2020
Q2 		$2.94M Buy
289,043
+4,550
+2% +$41.9K ﹤0.01% 2624
2020
Q1 		$2.31M Buy
284,493
+109,778
+63% +$951K ﹤0.01% 2597
2019
Q4 		$1.51M Buy
174,715
+8,584
+5% +$48.2K ﹤0.01% 3128
2019
Q3 		$1.02M Buy
166,131
+297
+0.2% +$2.4K ﹤0.01% 3227
2019
Q2 		$2.75M Buy
165,834
+14,370
+9% +$250K ﹤0.01% 2746
2019
Q1 		$2.53M Buy
151,464
+35,343
+30% +$509K ﹤0.01% 2708
2018
Q4 		$1.33M Buy
116,121
+29,917
+35% +$605K ﹤0.01% 2982
2018
Q3 		$3.45M Buy
86,204
+18,696
+28% +$532K ﹤0.01% 2596
2018
Q2 		$1.91M Buy
67,508
+26,493
+65% +$587K ﹤0.01% 2884
2018
Q1 		$626K Hold
41,015
– – ﹤0.01% 3320
2017
Q4 		$1.34M Buy
41,015
+14,739
+56% +$397K ﹤0.01% 2977
2017
Q3 		$616K Buy
26,276
+12,736
+94% +$143K ﹤0.01% 3290
2017
Q2 		$74K Sell
13,540
-485
-3% -$2.62K ﹤0.01% 3889
2017
Q1 		$99K Buy
14,025
+66
+0.5% +$355 ﹤0.01% 3831
2016
Q4 		$56K Buy
13,959
+44
+0.3% +$205 ﹤0.01% 3893
2016
Q3 		$101K Buy
13,915
+11
+0.1% +$74 ﹤0.01% 3800
2016
Q2 		$70K Buy
13,904
+923
+7% +$17K ﹤0.01% 3871
2016
Q1 		$279 Sell
12,981
-11
-0.1% -$233 ﹤0.01% 3510
2015
Q4 		$397K Buy
12,992
+3,547
+38% +$104K ﹤0.01% 3386
2015
Q3 		$315K Buy
9,445
+353
+4% +$19.9K ﹤0.01% 3463
2015
Q2 		$421K Buy
9,092
+3,821
+72% +$143K ﹤0.01% 3279
2015
Q1 		$189K Buy
+5,271
New +$231K ﹤0.01% 3602

Geode Capital Management's MRNS Position: Q1 2025 in Review

Geode Capital Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2025, closing a stake of 529,053 shares — an estimated $283K sold.

Geode Capital Management first reported a position in MRNS in Q1 2015 and held it in 40 quarters. The position peaked at $12.4M in Q4 2023. 0 funds tracked by Wall St. Rank hold MRNS as of Q1 2025.

  • Geode Capital Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2025 after selling out during the quarter.
  • Geode Capital Management sold 529,053 Marinus Pharmaceuticals, Inc shares in Q1 2025, an estimated $283K.
  • Geode Capital Management first reported a position in Marinus Pharmaceuticals, Inc in Q1 2015 and held it in 40 quarters.
  • Geode Capital Management's Marinus Pharmaceuticals, Inc position peaked at $12.4M in Q4 2023.
  • 0 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2025.

Based on Geode Capital Management's 13F filing for Q1 2025, filed 13 May 2025.